Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | survival of motor neuron 2, centromeric | Starlite/ChEMBL | No references |
Influenza A virus | Nonstructural protein 1 | Starlite/ChEMBL | No references |
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Echinococcus multilocularis | survival motor neuron protein 1 | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Echinococcus granulosus | survival motor neuron protein 1 | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Brugia malayi | hypothetical protein | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Mycobacterium tuberculosis | Hypothetical protein | Nonstructural protein 1 | 230 aa | 202 aa | 23.8 % |
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | retinoic acid receptor rxr beta a | 0.0208 | 0.4105 | 0.5712 |
Schistosoma mansoni | soluble guanylate cyclase gcy | 0.0346 | 0.796 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0346 | 0.796 | 0.796 |
Brugia malayi | hypothetical protein | 0.0286 | 0.6278 | 0.6278 |
Brugia malayi | Adenylate and Guanylate cyclase catalytic domain containing protein | 0.0104 | 0.121 | 0.121 |
Echinococcus multilocularis | retinoic acid receptor rxr beta a retinoic acid receptor rxr alpha a retinoic acid receptor rxr alpha | 0.0182 | 0.3386 | 0.4295 |
Loa Loa (eye worm) | hypothetical protein | 0.0419 | 1 | 1 |
Brugia malayi | Adenylate and Guanylate cyclase catalytic domain containing protein | 0.0346 | 0.796 | 0.796 |
Schistosoma mansoni | soluble guanylyl cyclase beta-3 | 0.0288 | 0.6358 | 0.7627 |
Echinococcus multilocularis | geminin | 0.0205 | 0.4023 | 0.5552 |
Loa Loa (eye worm) | hypothetical protein | 0.0286 | 0.6278 | 0.6278 |
Schistosoma mansoni | retinoic acid receptor RXR | 0.0208 | 0.4105 | 0.4289 |
Schistosoma mansoni | soluble guanylate cyclase gcy | 0.0305 | 0.6808 | 0.8293 |
Schistosoma mansoni | hypothetical protein | 0.0288 | 0.6358 | 0.7627 |
Echinococcus granulosus | geminin | 0.0205 | 0.4023 | 0.5552 |
Onchocerca volvulus | Bile acid receptor homolog | 0.0419 | 1 | 1 |
Loa Loa (eye worm) | guanylyl cyclase/natriuretic peptide receptor | 0.0346 | 0.796 | 0.796 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.4023 | 0.4168 |
Echinococcus multilocularis | survival motor neuron protein 1 | 0.0286 | 0.6278 | 1 |
Echinococcus granulosus | survival motor neuron protein 1 | 0.0286 | 0.6278 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.4023 | 0.4168 |
Loa Loa (eye worm) | hypothetical protein | 0.0104 | 0.121 | 0.121 |
Schistosoma mansoni | soluble guanylate cyclase gcy | 0.0305 | 0.6808 | 0.8293 |
Schistosoma mansoni | soluble guanylate cyclase gcy | 0.0305 | 0.6808 | 0.8293 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 0.0501 um | PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 3.6626 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 5.2213 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 7.9433 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 10 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 12.5893 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 18.3564 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase). (Class of assay: confirmatory) [Related pubchem assays: 2429 (Confirmation qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)), 2407 (Probe Development Summary for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)), 2427 (Thermal Shift Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase))] | ChEMBL. | No reference |
Potency (functional) | 32.6427 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.